Skip to main content
TLRY
NASDAQ Life Sciences

Tilray Brands Issues 2.6M Shares to Extinguish $12M in Convertible Debt

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.48
Mkt Cap
$538.813M
52W Low
$3.93
52W High
$23.2
52W Position info
14% above low
Off High info
81% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TLRY is trading near its 52-week low of $3.93 (14% above the low).

Summary

Tilray Brands exchanged $12 million of convertible debt for 2.64 million common shares, reducing debt but diluting existing shareholders.


Key Events · Financing and Capital Events · TLRY

  • Debt-for-Equity Exchange

    Tilray Brands issued 2,638,341 shares of common stock in exchange for $12 million aggregate principal amount of its 5.20% Convertible Senior Notes due June 15, 2027.

  • Share Dilution

    The issuance of 2.64 million new shares represents a notable dilutive event for existing shareholders, equivalent to approximately 2.2% of the company's market capitalization.

  • Debt Reduction

    The transaction successfully reduced the company's outstanding convertible debt by $12 million, improving its balance sheet.

  • Implied Share Price

    The shares were issued at an implied price of approximately $4.54 per share, which is slightly above the current market price of $4.48.


Analysis · TLRY · Life Sciences

Tilray Brands completed another series of private debt-for-equity exchanges, issuing 2.64 million common shares to eliminate $12 million in convertible senior notes. This move reduces the company's debt burden but results in significant dilution for existing shareholders, representing over 2% of the current market capitalization. This follows a pattern of similar debt-for-equity swaps by the company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLRY was trading at $4.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $538.8M. The 52-week trading range was $3.93 to $23.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLRY - Latest Insights

TLRY
Nov 02, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.51
Real-time Price: $1.91 info
Change: -$0.5957 (-24%) info
Market Cap: $279.318M info
TLRY
Oct 29, 2026, 8:18 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.70
Real-time Price: $1.91 info
Change: -$0.7852 (-29%) info
Market Cap: $279.318M info
TLRY
Oct 12, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.53
Real-time Price: $1.91 info
Change: -$1.61 (-46%) info
Market Cap: $279.318M info
TLRY
Oct 08, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $1.91 info
Change: -$1.70 (-47%) info
Market Cap: $279.318M info
TLRY
Oct 08, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.70
Real-time Price: $1.91 info
Change: -$1.79 (-48%) info
Market Cap: $279.318M info